Complex regional pain syndrome with associated chest wall dystonia: a case report.

David J. Irwin¹ and Robert J. Schwartzman¹

¹Drexel University College of Medicine, Department of Neurology, Philadelphia, PA, USA

Study Design: Case Report

David J Irwin MD
Robert J Schwartzman MD
Department of Neurology
Drexel University College of Medicine
New College Building
245 N 15th St
Philadelphia PA USA 19102
TEL: (215) 762-7090; FAX: (215) 762-3161;
e-mail: dirwin@drexelmed.edu (corresponding author),
robert.schwartzman@drexelmed.edu
Abstract

Patients with complex regional pain syndrome (CRPS) often suffer from an array of associated movement disorders, including dystonia of an affected limb. We present a case of a patient with long standing CRPS after a brachial plexus injury, who after displaying several features of the movement disorder previously, developed painful dystonia of chest wall musculature. Detailed neurologic examination found palpable sustained contractions of the pectoral and intercostal muscles in addition to surface allodynia. Needle electromyography of the intercostal and paraspinal muscles supported the diagnosis of dystonia. In addition, pulmonary function testing showed both restrictive and obstructive features in the absence of a clear cardiopulmonary etiology. Treatment was initiated with intrathecal baclofen and the patient had symptomatic relief and improvement of dystonia. This case illustrates a novel form of the movement disorder associated with CRPS with response to intrathecal baclofen treatment.

Keywords: complex regional pain syndrome, dystonia, movement disorder, dyspnea

Background
Complex regional pain syndrome (CRPS) is most often caused by a fracture or soft tissue injury of an extremity or a surgical procedure [1]. Factor analysis demonstrates that signs and symptoms of the syndrome cluster into four subgroups: 1) abnormalities in pain processing that cause allodynia, hyperalgesia and hyperpathia; 2) skin color and temperature change; 3) neurogenic edema, vasomotor and sudomotor abnormalities; and 4) a movement disorder and trophic changes [2]. The movement disorder is manifest as a combination of difficulty initiating and maintaining movement, weakness, postural and intention tremor, myoclonus, spasm, increased tone, abnormalities of reaching and grasping and dystonia [3,4]. Dystonia in CRPS is most likely a peripherally induced, focal dystonia [5].

In one study approximately 62% of CRPS patients were found to have an associated movement disorder, with dystonia being the most common [6]. Dystonia in CRPS patients is most common in the affected limb, with adduction of the arm and flexion of wrist and fingers in the upper extremity and internal rotation of the hip with plantar flexion and inversion of the foot in the lower extremity [3]. The presence of dystonia in CRPS patients is associated with longer disease duration and a younger age [6]. The onset of the movement disorder is variable but may precede other manifestations of the disease, and can occur five years or longer after disease onset [3,6].

The presence of dystonia in one extremity increases the risk of dystonia in a second extremity [6], with ipsilateral spread the most common pattern [3]. Generalized forms of dystonia can occur that involve all limbs [7,8]; however dystonia of axial muscles (intercostal, pectoralis and oblique muscles) that causes dyspnea has not been reported.
Case Presentation

The patient is a 51-year-old female who has been followed in neurologic consultation by the author (RJS) since 1987 for her chronic regional pain syndrome. She first presented with a brachial plexus traction injury after a fall. Pain symptoms progressed over the next two years to include total body burning and lancinating pains. At this point she had all factors for diagnosis of CRPS [9].

On physical examination the patient was moderately obese with an anteroflexed body posture and increased carrying angles of the arms. She had a paucity of spontaneous movement. Sensory examination showed severe generalized dynamic and static mechano allodynia and loss of surround inhibition to pinprick and a cold stimulus. In addition, she had severe generalized deep muscle sensitization and joint pain. She had hyperalgesia to pinprick and “wind up” as well as cold allodynia in all quadrants of her body. She had longstanding chest pain in the distribution of the intercostobrachial nerve [10].

Autonomic involvement was demonstrated by cold extremities and generalized hyperhidrosis and was associated with moderate neurogenic edema in the lower extremities and livedo reticularis of the skin. Dystonic posturing of the lower extremity was noted early during a few visits and was evidenced by internal rotation of the hip and plantar flexion and inversion of the foot. In addition to overt dystonia, the patient developed ambulatory dysfunction due to weakness and difficulty initiating movements. On one occasion she noted her legs did “not feel like hers.” She had difficulty initiating and maintaining fine movements in all extremities. On one visit a postural and intention tremor of the hands and head was noted.
She had failed numerous surgical and medical interventions and developed opiate dependency requiring high doses of intrathecal dilaudid via a subcutaneous pump. Other medical problems included adrenal insufficiency, obstructive sleep apnea that required maintenance on nocturnal bi-level positive airway pressure, chronic gastroparesis, chronic elevation of the right hemi-diaphragm, and hypothyroidism.

Approximately twenty-four years after the onset of her CRPS, the patient began having respiratory symptoms of dyspnea on exertion. Palpation of the chest wall showed restrictive chest expansion and sustained contractions of the intercostal musculature, consistent with dystonia. Electromyography (EMG) of the transverses thoraces muscles and paraspinal muscles at T6 and T10 showed normal insertional activity and motor unit morphology. During neurophysiologic testing there was an inability to relax these muscles voluntarily by the patient.

Initial pulmonary function testing showed a mixed restrictive and obstructive picture with a response to bronchodilators (Table 1). Spirometry study met American thoracic society criteria for acceptability [11], with the exception of forced vital capacity on the first study due to fatigue. CT scanning of the chest did not display any features of interstitial lung disease. Echocardiogram showed grade I diastolic dysfunction with no structural heart, valve disease, or pulmonary hypertension.

After receiving a five-day continuous intravenous sub-anesthetic dose of ketamine by infusion (40mg/hr; midazolam 4 mg/6hr; 0.1 mg of clonidine), her intrathecal dilaudid was gradually weaned from 79 mg/day to 21 mg/day. In addition, intrathecal baclofen was added at an initial dose of 75 μg/day. Baclofen was up titrated by approximately 50 μg/day every two weeks to a final dose of 600 μg/day. The patient experienced
symptomatic relief of her chest wall discomfort and dyspnea beginning at doses of 125 μg of baclofen per day. Chest wall dystonia was much improved on serial neurologic examinations. Pulmonary function testing results were not significantly changed after baclofen treatment (Table 1). She was maintained at a dose of 600 μg/day of intrathecal baclofen and has been asymptomatic in regard to lethargy, weakness, nausea, headaches, or psychosis.

Conclusions

To our knowledge, this is the first report of dystonia of the chest wall musculature associated with CRPS. The electrodiagnostic evidence of dystonia was limited to patient-dependent factors, as the EMG testing showed normal motor unit activation and morphology. It should be noted that the EMG was performed while the patient was receiving 425 μg/day of intrathecal baclofen, which could affect motor unit activation. A neurophysiologic study of dystonia in CRPS patients found a similar inability to alter muscle activity voluntarily, in addition to decreased inhibition from activation of antagonist muscle groups [12]. One could argue that the observed inability to relax the chest was musculature was psychogenic; however, voluntary sustained contraction of these axial muscle groups would be very difficult to perform compared to an extremity. In addition, this patient did not display pseudoneurological signs others have argued to be present in CRPS [13].

The significance of the chest wall dystonia in regards to pulmonary symptoms is unclear, but most likely contributes in part to the restrictive pulmonary function pattern observed. Patients with idiopathic and secondary dystonia have been noted to have
excessive contractions of the diaphragm and upper airways contributing to symptoms of dyspnea [14]. This patient also had obstructive features and a response to bronchodilators, which most likely represents concomitant asthmatic disease. There was no intrinsic disease of the lung parenchyma on CT scanning that could be responsible for her obstructive and restrictive pulmonary function. Vocal cord involvement as a cause for her dyspnea was also unlikely, as there was no dysphonia. Her body habitus, chest wall pain, and paralysis of the right hemi-diaphragm can also contribute to restrictive lung disease. The diaphragm paralysis in this patient is most likely another manifestation of dystonia as spasmodic contraction of the diaphragm may be seen in dystonic patients [14].

The mechanism of dystonia in CRPS is not completely understood but is generally thought to involve neural circuits that mediate sensory-motor integration [15,16,17]. Recent studies demonstrate impaired inhibition both at cortical and spinal cord levels [18,19,20]. Present evidence suggests that a major component of the mechanism of dystonia in CRPS involves disinhibition of painful nociceptive withdrawal reflexes in the spinal cord [6]. These reflexes are initiated by activity in C and A-delta primary pain fibers that colocalize vasoactive neuropeptides with glutamate and are also pivotal in neurogenic inflammation [21]. Substance P is released from pain afferents and activates NK1 receptors on lamina I neurons of the dorsal horn that is important in the induction of long term potentiation of these pain transmission neurons [22]. Evidence of spinal cord inflammation has been demonstrated in CRPS patients who have increased levels of inflammatory cytokines in their spinal fluid [23,24]. Pathologic examination of a severe longstanding CRPS patient has shown microglial and astrocytic activation most
prominent at the segmental level of injury, but also as a gradient spread throughout the spinal cord bilaterally [25]. It is possible that this inflammatory activation of the spinal cord resulted in dystonia of the axial musculature through disinhibition of GABAergic inhibitory neurons of the dorsal horn at thoracic levels mediated by SP and inflammatory cytokines. The presented patient has suffered with CRPS for over twenty years and the one autopsied had a six year course suggesting that axial dystonia is a late manifestation of the syndrome.

Intrathecal baclofen is effective in treatment of the limb dystonia of CRPS at a mean dose of 415 μg/day [26]. Our patient responded at 600 μg/day. Symptomatic improvement from intrathecal baclofen implicates spinal cord involvement in this form of dystonia. Its greatest concentration is in the dorsal horn of the spinal cord in primary afferent fibers [27]. The axial dystonia seen in this patient suggests a link between immune mediated cytokine release and substance P activation of nocifensor reflexes in the thoracic cord in the axial dystonia of CRPS.

Consent

Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing Interests

The authors declare that they have no competing interests.

Author’s Contributions
RJS formulated the project. DI and RJS contributed in taking the patient history, physical exam, and preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgments

There was no private or public funding for this study.

References


[16] Huang YZ, Trender-Gerhard I, Edwards MJ et al. Motor system inhibition in
dopa-responsive dystonia and its modulation by treatment. *Neurol* 2006, 66(7): 1088-
1090.


Neurophysiologic aspects of patients with generalized or multifocal tonic dystonia of

[19] Schouten AC, Van de Beek WJ, Van Hilten JJ, Van der Helm FC. Proprioceptive
1-8.

in complex regional pain syndrome (CRPS) type I of the hand. *Neurol* 2003, 61(4):
515-519.


Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. *Pain.*


Table 1
Pulmonary function testing results before and after intrathecal baclofen treatment.

<table>
<thead>
<tr>
<th>Study 1†</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FVC</td>
<td>FEV1</td>
<td>FEF 25-75%</td>
<td>PEF</td>
<td>TLC</td>
<td>RV</td>
</tr>
<tr>
<td>Pre-Bronchodilator</td>
<td>1.83 L</td>
<td>1.60 L</td>
<td>2.20 L/sec</td>
<td>5.34 L/sec</td>
<td>2.71 L</td>
<td>0.88 L</td>
</tr>
<tr>
<td></td>
<td>(44% Ret)</td>
<td>(49% Ret)</td>
<td>(73% Ref)</td>
<td>(71% Ref)</td>
<td>(45% (40% (44% Ref) Ref)</td>
<td></td>
</tr>
<tr>
<td>Post-Bronchodilator</td>
<td>2.06 L</td>
<td>1.78 L</td>
<td>2.44 L/sec</td>
<td>4.62 L/sec</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>(50% Ref)</td>
<td>(54% Ref)</td>
<td>(81% Ref)</td>
<td>(62% Ref)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study 2††</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Bronchodilator</td>
<td>1.95 L</td>
<td>1.57 L</td>
<td>1.59 L/sec</td>
<td>4.74 L/sec</td>
<td>3.07 L</td>
<td>1.10 L</td>
</tr>
<tr>
<td></td>
<td>(47% Ref)</td>
<td>(49% Ref)</td>
<td>(53% Ref)</td>
<td>(64% Ref)</td>
<td>(52% (50% (36% Ref) Ref)</td>
<td></td>
</tr>
<tr>
<td>Post-Bronchodilator</td>
<td>2.18 L</td>
<td>1.79 L</td>
<td>1.97 L/sec</td>
<td>4.89 L/sec</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>(53% Ref)</td>
<td>(55% Ref)</td>
<td>(66% Ref)</td>
<td>(66% Ref)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

† Patient intrathecal medication dose at time of study: Baclofen 0 µg/day, Dilaudid 26.5 mg/day
†† Patient intrathecal medication dose at time of study: Baclofen 400 µg/day, Dilaudid 21.5mg/day